Neptune

▲The first dose of the 9-valent HPV vaccine for men in universities across the country was given in Shenzhen University Hospital. Photo courtesy of the interviewee

On October 18, a number of new indications of Merck's nine-valent HPV vaccine have been approved by the National Medical Products Administration, which is suitable for vaccination of men aged 0~0 years old, marking that China has entered a new stage of "joint prevention of HPV-related cancers and diseases between men and women". On 0/00, the first shot of the 9-valent HPV vaccine for men was given in Shenzhen University Hospital after the approval of the 9-valent HPV vaccine for men across the country.

At the vaccination site, Fang from Shenzhen University, as a male recipient of the first dose of HPV 9-valent vaccine, shared his feelings. "The vaccination process was smooth, and there was no discomfort after the shot." Fang said that he had learned that HPV infection does not discriminate between men and women, and it is also very necessary for men to receive HPV vaccination.

It is reported that all vaccination sites in Shenzhen have been prepared, and male citizens can make appointments for vaccination nearby. It is understood that at present, men have two HPV vaccines to choose from, one is the quadrivalent HPV vaccine, which is suitable for men aged 26~0 years old; The other is the nine-valent HPV vaccine, which is suitable for men aged 0~0 years old. (Reporter Zhou Qian)